The National Health Surveillance Agency (Anvisa) approved the use of another weekly injectable medication to reduce overweight and obesity.
The active ingredient in the injection is semaglutide. It is a substance similar to the hormone GLP-1, which we naturally produce in the intestine and which indicates the feeling of satiety to the nervous system. Endocrinologist Pedro Leão says that the substance generates a series of effects that help with weight loss.
The semaglutide injection should only be given once a week. Research carried out by the laboratory that produces the medication showed that the medication promoted an average reduction of 17% in body weight.
Despite the benefits, endocrinologist Pedro Leão warns that a trusted professional should be sought to indicate or not the treatment.
Even after approval, there is still no set date for marketing the drug.
